Related Experiment Videos
The TGF beta receptor endoglin in systemic sclerosis.
A A Dharmapatni1, M D Smith, M J Ahern
1Department of Immunology, Allergy, and Arthritis, Flinders Medical Centre, Bedford Park, South Australia.
Asian Pacific Journal of Allergy and Immunology
|May 15, 2002
Summary
Endoglin (CD105) is elevated on skin blood vessels in systemic sclerosis patients, indicating potential endothelial activation. However, levels on circulating monocytes and in serum remain normal, suggesting localized effects in the skin.
Area of Science:
- Immunology
- Dermatology
- Rheumatology
Background:
- Systemic sclerosis is a complex autoimmune disease characterized by fibrosis and vascular abnormalities.
- Endoglin (CD105), a TGF-beta receptor, is involved in angiogenesis and vascular remodeling.
- Understanding endoglin's role in systemic sclerosis may offer insights into disease pathogenesis.
Purpose of the Study:
- To investigate endoglin expression on dermal endothelial cells, peripheral blood monocytes, and serum levels in systemic sclerosis patients.
- To compare these levels with healthy controls and patients with other rheumatic and inflammatory skin disorders.
- To explore potential correlations between endoglin expression and endothelial activation in systemic sclerosis.
Main Methods:
- Immunohistochemistry was used to assess endoglin on dermal endothelial cells.
- Flow cytometry was employed to analyze endoglin expression on peripheral blood monocytes.
- Enzyme-linked immunosorbent assay (ELISA) measured free and bound serum endoglin levels.
- Comparisons were made between systemic sclerosis patients, healthy controls, and patients with inflammatory skin/rheumatic disorders.
Main Results:
- Endoglin was significantly upregulated on dermal blood vessels in systemic sclerosis patients compared to healthy controls (p < 0.05).
- No significant differences in endoglin expression were observed on circulating monocytes between systemic sclerosis patients and controls.
- Endoglin expression on monocytes was influenced by isolation techniques and whole blood culture; it was elevated in rheumatoid arthritis joint fluid.
- Circulating free and bound serum endoglin levels did not differ between systemic sclerosis patients and healthy controls.
Conclusions:
- Endoglin expression is significantly enhanced on dermal endothelial cells in systemic sclerosis.
- Levels of endoglin on circulating monocytes and in serum are within normal limits in systemic sclerosis.
- The upregulation of endoglin on dermal vessels may indicate endothelial activation in systemic sclerosis, though its functional significance requires further investigation.